Retatrutide, from Soma Pharmaceuticals , is attracting increasing attention as a innovative therapy for metabolic management . This dual-action drug integrates the mechanism of a GLP-1 receptor agonist and a GIP receptor agonist , aiming to not only promote reduced body fat but also address related metabolic conditions . Early patient studies have